Related Experiment Video
Updated: May 13, 2025
08:16
Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture
Published on: February 11, 2019
8.5K
A Comparative Study of Pancreatic Acinar Cell Carcinoma: A Case-Control Study
Bor-Shiuan Shyr1,2, Ting-Chung Chen1,2, Shin-E Wang1,2
1Division of General Surgery, Department of Surgery and Therapeutic and Research Center of Pancreatic Cancer Taipei Veterans General Hospital Taipei Taiwan (ROC).
Health Science Reports
|April 14, 2025
Summary
Pancreatic acinar cell carcinoma (PACC) shows lower rates of lymph node involvement and invasion compared to pancreatic ductal adenocarcinoma (PDAC). However, survival outcomes are similar between resectable PACC and PDAC after matching.
Area of Science:
- Oncology
- Gastroenterology
- Surgical Pathology
Background:
- Pancreatic acinar cell carcinoma (PACC) is a rare pancreatic cancer.
- Understanding PACC's clinical features and survival is crucial for patient management.
Purpose of the Study:
- To elucidate the clinical characteristics of PACC.
- To compare survival outcomes of PACC with pancreatic ductal adenocarcinoma (PDAC).
Main Methods:
- Retrospective analysis of PACC patients.
- Propensity score matching (PSM) to compare PACC and PDAC cohorts.
- Evaluation of clinical features, tumor characteristics, and survival rates.
Main Results:
- PACC cases showed a median tumor size of 5.9 cm, with 60% in the pancreatic head.
- Elevated serum lipase was noted in 64.3% of PACC patients.
- Resectable PACC had significantly lower rates of lymph node involvement, lymphovascular invasion (LVI), and perineural invasion (PNI) compared to PDAC.
Conclusions:
- PACC exhibits distinct pathological features with lower rates of nodal and invasive spread than PDAC.
- While PACC shows favorable features, survival outcomes are comparable to PDAC after propensity score matching.
